Scholar Rock Q3 net loss $42.4M; SAPPHIRE enrollment complete, topline Q4 2024

Scholar Rock Holding Corp

2023-Q3 EPS reported -$1.49

Net loss $42.4M (vs $43.3M YoY); no revenue; cash $218.6M + $92.5M Oct offering extends runway into H2 2025.
Completed enrollment of Phase 3 SAPPHIRE trial for apitegromab in SMA; topline data expected Q4 2024.
Expanding into cardiometabolic with SRK-439; plans Phase 2 trial with apitegromab + GLP-1 RA in 2024.
Phase 1 DRAGON trial of SRK-181 showed 21.4% ORR in ccRCC; enrollment completion in Dec 2023.
Completed $98M public offering in October 2023; proceeds support pipeline expansion.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Scholar Rock Holding Corp reported third quarter ended September 30, 2023 results: net income $42.4 million.

Period: third quarter ended September 30, 2023
Net income: $42.4 million
Result: reported results

Exact text from the filing

For the quarter ended September 30, 2023, net loss was $42.4 million compared to a net loss of $43.3 million for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Scholar Rock Holding Corp filing history →

Source: SEC EDGAR

accession 0001157523-23-001660

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.